Literature DB >> 33668714

Intractable Itch in Atopic Dermatitis: Causes and Treatments.

Yoshie Umehara1, Chanisa Kiatsurayanon2, Juan Valentin Trujillo-Paez1, Panjit Chieosilapatham3, Ge Peng1, Hainan Yue1, Hai Le Thanh Nguyen1, Pu Song4, Ko Okumura1, Hideoki Ogawa1, François Niyonsaba1,5.   

Abstract

Itch or pruritus is the hallmark of atopic dermatitis and is defined as an unpleasant sensation that evokes the desire to scratch. It is also believed that itch is a signal of danger from various environmental factors or physiological abnormalities. Because histamine is a well-known substance inducing itch, H1-antihistamines are the most frequently used drugs to treat pruritus. However, H1-antihistamines are not fully effective against intractable itch in patients with atopic dermatitis. Given that intractable itch is a clinical problem that markedly decreases quality of life, its treatment in atopic dermatitis is of high importance. Histamine-independent itch may be elicited by various pruritogens, including proteases, cytokines, neuropeptides, lipids, and opioids, and their cognate receptors, such as protease-activated receptors, cytokine receptors, Mas-related G protein-coupled receptors, opioid receptors, and transient receptor potential channels. In addition, cutaneous hyperinnervation is partly involved in itch sensitization in the periphery. It is believed that dry skin is a key feature of intractable itch in atopic dermatitis. Treatment of the underlying conditions that cause itch is necessary to improve the quality of life of patients with atopic dermatitis. This review describes current insights into the pathophysiology of itch and its treatment in atopic dermatitis.

Entities:  

Keywords:  atopic dermatitis; dry skin; intractable itch; itch/pruritus; keratinocyte; sensory nerve fiber

Year:  2021        PMID: 33668714      PMCID: PMC7996203          DOI: 10.3390/biomedicines9030229

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  110 in total

1.  The human cathelicidin LL-37 host defense peptide upregulates tight junction-related proteins and increases human epidermal keratinocyte barrier function.

Authors:  Toshihiro Akiyama; François Niyonsaba; Chanisa Kiatsurayanon; Toan The Nguyen; Hiroko Ushio; Tsutomu Fujimura; Takashi Ueno; Ko Okumura; Hideoki Ogawa; Shigaku Ikeda
Journal:  J Innate Immun       Date:  2014-05-23       Impact factor: 7.349

Review 2.  Neurogenic inflammation in human and rodent skin.

Authors:  M Schmelz; L J Petersen
Journal:  News Physiol Sci       Date:  2001-02

3.  Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema.

Authors:  Anitta Järvikallio; Ilkka T Harvima; Anita Naukkarinen
Journal:  Arch Dermatol Res       Date:  2003-01-31       Impact factor: 3.017

4.  Transepidermal water loss, serum IgE and beta-endorphin as important and independent biological markers for development of itch intensity in atopic dermatitis.

Authors:  C-H Lee; H-Y Chuang; C-C Shih; S-B Jong; C-H Chang; H-S Yu
Journal:  Br J Dermatol       Date:  2006-06       Impact factor: 9.302

5.  Activation of proteinase-activated receptors induces itch-associated response through histamine-dependent and -independent pathways in mice.

Authors:  Kenichiro Tsujii; Tsugunobu Andoh; Jung-Bum Lee; Yasushi Kuraishi
Journal:  J Pharmacol Sci       Date:  2008-11-06       Impact factor: 3.337

6.  Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP.

Authors:  Vassili Soumelis; Pedro A Reche; Holger Kanzler; Wei Yuan; Gina Edward; Bernhart Homey; Michel Gilliet; Steve Ho; Svetlana Antonenko; Annti Lauerma; Kathleen Smith; Daniel Gorman; Sandra Zurawski; Jon Abrams; Satish Menon; Terri McClanahan; Rene de Waal-Malefyt Rd; Fernando Bazan; Robert A Kastelein; Yong-Jun Liu
Journal:  Nat Immunol       Date:  2002-06-10       Impact factor: 25.606

7.  The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study.

Authors:  O Nemoto; M Furue; H Nakagawa; M Shiramoto; R Hanada; S Matsuki; S Imayama; M Kato; I Hasebe; K Taira; M Yamamoto; R Mihara; K Kabashima; T Ruzicka; J Hanifin; Y Kumagai
Journal:  Br J Dermatol       Date:  2015-12-19       Impact factor: 9.302

8.  Painful stimuli evoke itch in patients with chronic pruritus: central sensitization for itch.

Authors:  A Ikoma; M Fartasch; G Heyer; Y Miyachi; H Handwerker; M Schmelz
Journal:  Neurology       Date:  2004-01-27       Impact factor: 9.910

9.  Possible Antipruritic Mechanism of Cyclosporine A in Atopic Dermatitis.

Authors:  Kyi Chan Ko; Mitsutoshi Tominaga; Yayoi Kamata; Yoshie Umehara; Hironori Matsuda; Nobuaki Takahashi; Katsunari Kina; Mayuko Ogawa; Hideoki Ogawa; Kenji Takamori
Journal:  Acta Derm Venereol       Date:  2016-06-15       Impact factor: 4.437

10.  Behavioral model of itch, alloknesis, pain and allodynia in the lower hindlimb and correlative responses of lumbar dorsal horn neurons in the mouse.

Authors:  T Akiyama; M Nagamine; M I Carstens; E Carstens
Journal:  Neuroscience       Date:  2014-02-12       Impact factor: 3.590

View more
  6 in total

Review 1.  Promising Natural Products in New Drug Design, Development, and Therapy for Skin Disorders: An Overview of Scientific Evidence and Understanding Their Mechanism of Action.

Authors:  Nurul Amirah Mohd Zaid; Mahendran Sekar; Srinivasa Reddy Bonam; Siew Hua Gan; Pei Teng Lum; M Yasmin Begum; Nur Najihah Izzati Mat Rani; Jaishree Vaijanathappa; Yuan Seng Wu; Vetriselvan Subramaniyan; Neeraj Kumar Fuloria; Shivkanya Fuloria
Journal:  Drug Des Devel Ther       Date:  2022-01-06       Impact factor: 4.162

2.  Evaluating the Effectiveness of Intranasal Butorphanol in Reducing Chronic Itch.

Authors:  Angelina Labib; Teresa Ju; Zoe Morgan Lipman; Gil Yosipovitch
Journal:  Acta Derm Venereol       Date:  2022-06-09       Impact factor: 3.875

Review 3.  Opioidergic Signaling-A Neglected, Yet Potentially Important Player in Atopic Dermatitis.

Authors:  Dorottya Ádám; József Arany; Kinga Fanni Tóth; Balázs István Tóth; Attila Gábor Szöllősi; Attila Oláh
Journal:  Int J Mol Sci       Date:  2022-04-08       Impact factor: 6.208

Review 4.  Acupuncture for the Treatment of Itch: Peripheral and Central Mechanisms.

Authors:  Yi Tang; Shirui Cheng; Jin Wang; Yin Jin; Haodong Yang; Qihui Lin; Sanmei Xu; Lin Hui; Quanying Yin; Ying Yang; Xi Wu
Journal:  Front Neurosci       Date:  2022-03-30       Impact factor: 4.677

5.  Chronic Pruritus in Atopic Patients Treated with Dupilumab: Real Life Response and Related Parameters in 354 Patients.

Authors:  Luca Mastorino; François Rosset; Federica Gelato; Michela Ortoncelli; Giovanni Cavaliere; Pietro Quaglino; Simone Ribero
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-17

Review 6.  Pruritus: A Sensory Symptom Generated in Cutaneous Immuno-Neuronal Crosstalk.

Authors:  Attila Gábor Szöllősi; Attila Oláh; Erika Lisztes; Zoltán Griger; Balázs István Tóth
Journal:  Front Pharmacol       Date:  2022-03-07       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.